ZURA Zura Bio
- 5.209
- +0.049+0.95%
Zura Bio News
Zura Bio Ltd (ZURA) Q1 2024 Earnings: Financial and Strategic Developments
Zura Bio Is Maintained at Outperform by Oppenheimer
Zura Bio Is Maintained at Outperform by Oppenheimer
Oppenheimer: Maintaining the Zura Bio (ZURA.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $16.00 to $21.00.
Oppenheimer: Maintaining the Zura Bio (ZURA.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $16.00 to $21.00.
Oppenheimer Adjusts Zura Bio Price Target to $21 From $16, Maintains Outperform Rating
Zura Bio (ZURA) has an average rating of Buy and price targets ranging from $10 to $26, according to analysts polled by Capital IQ. Price: 4.61, Change: +0.01, Percent Change: +0.11
Zura Bio Q1 2024 GAAP EPS $(0.02) Beats $(0.23) Estimate
Zura Bio (NASDAQ:ZURA) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.23) by 91.3 percent.
10-Q: Quarterly report
Zura Bio Projected Cash Runway Extends Support for Ops Through 2027 >ZURA
Zura Bio Projected Cash Runway Extends Support for Ops Through 2027 >ZURA
Zura Bio 1Q Loss $7.75M >ZURA
Zura Bio 1Q Loss $7.75M >ZURA
Press Release: Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights -- Ended Q1 2024 with $89.8 million in cash and closed oversubscribed $112.5 million private placement i
Zura Bio Initiated at Overweight by Piper Sandler
Zura Bio Initiated at Overweight by Piper Sandler
Piper Sandler Initiates Coverage On Zura Bio With Overweight Rating, Announces Price Target of $26
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Zura Bio with a Overweight rating and announces Price Target of $26.
Analysts Are Bullish on These Healthcare Stocks: Irhythm Technologies (IRTC), Zura Bio (ZURA)
Behind The Uptrend: Understanding Zura Bio (ZURA) Stock Surge
The shares of Zura Bio Limited (NASDAQ: ZURA) are currently witnessing a remarkable surge, demonstrating a significant increase of 20.17% during the current trading session, reaching a value of $4.35. This substantial uptrend in the price of ZUR stock follows recent equity actions, as there is no immediate discernible catalyst directly responsible for this surge. ...
12 Health Care Stocks Moving In Friday's Intraday Session
GainersBiodexa Pharmaceuticals (NASDAQ:BDRX) stock rose 61.4% to $1.17 during Friday's regular session. The company's market cap stands at $5.1 million. Agenus (NASDAQ:AGEN) shares rose 32.53% to $11.
Zura Bio Insider Bought Shares Worth $3,715,000, According to a Recent SEC Filing
Someit Sidhu, Director, on April 22, 2024, executed a purchase for 1,186,901 shares in Zura Bio (ZURA) for $3,715,000. Following the Form 4 filing with the SEC, Sidhu has control over a total of 3,675
Director Amit Munshi Acquires 159,744 Shares of Zura Bio Ltd (ZURA)
Zura Bio Raises $112.5M Through Private Placement Deal
Zura Bio Announces Oversubscribed $112.5 Million Private Placement
- Financing includes new and existing leading life sciences institutional investors - Strengthened balance sheet expected to fund operations through 2027 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical
Zura Bio Issues Key Update for Investors
Zura Bio Announces That Robert Lisicki Has Assumed The Role Of Chief Executive Officer And A Director
Succeeds Founding CEO, Dr. Someit Sidhu, who will continue as a Board DirectorRecognized as inspirational industry leader with exceptional R&D, commercial and global executive experienceOutstanding pr
Analysis
Price Target
No Data
